News & Blog

Letter to the FA Community from Astellas Pharma

Meet The Community: Christin Haun

Webinar Recording: PTC Therapeutics Vatiquinone Program January 2025 Update

Janaury 2025 – Advocacy Newsletter

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

Living with FA, Leading in Research: FA Patient-Researchers Present at ICAR 2024

Press Release & Community Letter: Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia

December 2024 – Advocacy Newsletter

PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich’s Ataxia

2024 FARA Energy Ball Recap

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia